Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility [Yahoo! Finance]
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $84.00 to $88.00. They now have an "overweight" rating on the stock.